Caliway Set to Showcase Innovative CBL-514 Data Combining with GLP-1R Therapy at ECO 2026

Caliway Biopharmaceuticals to Present at ECO 2026

Caliway Biopharmaceuticals is stepping into the spotlight as it prepares to present significant preclinical research findings on its innovative weight-loss drug candidate, CBL-514. The data has been selected for an oral presentation at the prestigious European Congress on Obesity (ECO 2026), scheduled to take place from May 12 to 15, 2026, in Istanbul, Türkiye. This selection not only emphasizes the promising efficacy of CBL-514 but also its potential role as a complementary approach to existing strategies in obesity treatment.

Dr. Arya M. Sharma, a recognized authority in obesity medicine and scientific advisor for Caliway, will be leading the presentation. Dr. Sharma's extensive experience in the field will provide invaluable insights into the mechanisms behind CBL-514's fat-reduction capabilities, particularly its unique approach to inducing adipocyte apoptosis. Such mechanisms stand apart from traditional weight-loss therapies, which often focus solely on appetite suppression, presenting a new avenue for more effective treatment options.

The upcoming presentation, titled "CBL-514: An Adipocyte-Apoptosis Agent Enhances GLP-1 Induced Weight Loss and Attenuates Weight Regain In Diet-Induced Obese Rats," will delve deep into the scientific methodologies and outcomes of CBL-514’s clinical trials. The findings highlight CBL-514’s differentiated action in combating obesity by directly targeting fat cells rather than merely curbing appetite. This method not only enhances weight loss but could significantly minimize post-treatment weight regain, which is a common issue in current methodologies.

During the congress, Caliway seeks to engage with health experts, researchers, and pharmaceutical leaders within the European sphere of obesity treatment. With the increasing global concern regarding obesity and related metabolic disorders, the timing of this presentation is pivotal. ECO is one of the leading international platforms dedicated to knowledge sharing in the context of obesity, bringing together almost 4,000 specialists from over 70 countries with the aim of promoting the latest developments in this field.

Vivian Ling, the CEO of Caliway, expressed enthusiasm regarding the opportunity to showcase CBL-514 at such a significant event. She emphasized the company's commitment to revolutionizing weight-loss solutions and enhancing scientific collaborations worldwide. Dr. Sharma's expertise, especially his history of collaboration with major pharmaceutical firms like Novo Nordisk and Eli Lilly, reinforces the company's credibility within the industry.

Caliway's ongoing advancements with CBL-514 encompass the reduction of subcutaneous fat and management of conditions such as moderate-to-severe cellulite. The firm has conducted 10 clinical trials involving 544 subjects, all of which have successfully met established efficacy and safety milestones.

As the world increasingly acknowledges the battle against obesity, the spotlight will undoubtedly be on innovative solutions like CBL-514. The upcoming presentation at ECO 2026 could redefine therapeutic strategies in obesity treatment, marking a significant milestone in Caliway's journey as they strive to be a leader in aesthetic medicine and beyond.

In addition to the scientific presentation, Caliway aims to explore further collaborative opportunities to fortify its development strategy internationally in the obesity and metabolic disease landscape. With such impressive advancements and a clear focus on addressing unmet medical needs, Caliway positions itself as a company to watch in the ongoing war against obesity.

For further information about Caliway and its innovative therapies, please visit Caliway Biopharmaceuticals.